Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 2/20 | 0.42 |
| ▸ | CNR2 | P34972 | 15/20 | 0.36 |
| ▸ | CNR1 | P21554 | 12/20 | 0.36 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.32 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.32 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30292391 | 1.00 | PTGER4 (0.42) | PTGER4CNR2CNR1FAAHPTGDR | |
| SCHEMBL21482091 | 0.90 | PTGER4 (0.43) | PTGER4CNR2CNR1FAAH | |
| SCHEMBL21458276 | 0.89 | PTGER4 (0.43) | PTGER4CNR2CNR1FAAH | |
| SCHEMBL21506730 | 0.89 | PTGER4 (0.43) | PTGER4CNR2CNR1FAAH | |
| SCHEMBL27323020 | 0.88 | PTGER4 (0.46) | PTGER4CNR2CNR1EGLN1 | |
| SCHEMBL21458112 | 0.88 | PTGER4 (0.46) | PTGER4CNR2CNR1EGLN1 | |
| SCHEMBL20541645 | 0.88 | PTGER4 (0.56) | PTGER4CNR2CNR1PTGDR | |
| SCHEMBL31203583 | 0.87 | PTGER4 (0.47) | PTGER4CNR2CNR1FAAHPTGDR | |
| SCHEMBL21458214 | 0.87 | PTGER4 (0.47) | PTGER4CNR2CNR1FAAHPTGDR | |
| SCHEMBL21458170 | 0.86 | PTGER4 (0.40) | PTGER4CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210008046-A1 | BICYCLIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER | TEMPEST THERAPEUTICS, INC. | 2021-01-14 | — | — | US | claimed |
| EP-3612517-A1 | BICYCLIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER | Tempest Therapeutics, Inc. (US) | 2020-02-26 | — | — | EP | claimed |
| WO-2018195123-A1 | BICYCLIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER | TEMPEST THERAPEUTICS, INC. (US) | 2018-10-25 | — | — | WO | claimed |
| US-11738009-B2 | Bicyclic compounds and their use in the treatment of cancer | TEMPEST THERAPEUTICS, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| US-11738009-B2 | Bicyclic compounds and their use in the treatment of cancer | TEMPEST THERAPEUTICS, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| US-11638704-B2 | Bicyclic compounds and their use in the treatment of cancer | TEMPEST THERAPEUTICS, INC. (US) | 2023-05-02 | — | — | US | disclosed |
| US-11638704-B2 | Bicyclic compounds and their use in the treatment of cancer | TEMPEST THERAPEUTICS, INC. (US) | 2023-05-02 | — | — | US | disclosed |
| US-20210387985-A1 | BICYCLIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER | TEMPEST THERAPEUTICS, INC. | 2021-12-16 | — | — | US | disclosed |
| US-11066405-B2 | Bicyclic compounds and their use in the treatment of cancer | TEMPEST THERAPEUTICS, INC. (US) | 2021-07-20 | — | — | US | disclosed |
| US-20210008046-A1 | BICYCLIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER | TEMPEST THERAPEUTICS, INC. | 2021-01-14 | — | — | US | disclosed |
| US-20200283438-A1 | BICYCLIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER | TEMPEST THERAPEUTICS, INC. | 2020-09-10 | — | — | US | disclosed |
| EP-3612517-A1 | BICYCLIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER | Tempest Therapeutics, Inc. (US) | 2020-02-26 | — | — | EP | disclosed |
| WO-2018195123-A1 | BICYCLIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER | TEMPEST THERAPEUTICS, INC. (US) | 2018-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11066405-B2 | Bicyclic compounds and their use in the treatment of cancer | PTGER4, PTGER1, PTGER3 | PTGER4 1/4885CNR2 133/4885CNR1 148/4885 |
| US-20210008046-A1 | BICYCLIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER | PTGER4, PTGER1, PTGER3 | PTGER4 1/4885CNR2 133/4885CNR1 148/4885 |
| US-11738009-B2 | Bicyclic compounds and their use in the treatment of cancer | PTGER4, PTGER1, PTGER3 | PTGER4 1/4885CNR2 133/4885CNR1 148/4885 |
| US-20210387985-A1 | BICYCLIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER | PTGER4, PTGER1, PTGER3 | PTGER4 1/4885CNR2 126/4885CNR1 148/4885 |
| US-11638704-B2 | Bicyclic compounds and their use in the treatment of cancer | PTGER4, PTGER1, PTGER3 | PTGER4 1/4885CNR2 126/4885CNR1 148/4885 |
| US-20200283438-A1 | BICYCLIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER | PTGER4, PTGER1, PTGER3 | PTGER4 1/4885CNR2 133/4885CNR1 148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.